Literature DB >> 16522543

The genetics of the myelodysplastic syndromes: classical cytogenetics and recent molecular insights.

Sindhu Cherian1, Adam Bagg.   

Abstract

Myelodysplastic syndromes (MDS) are a complex group of clonal hematopoietic disorders with an attendant diverse array of associated genetic changes. Conventional cytogenetics plays a prominent and well-established role in determining the contemporary diagnosis and prognosis of these disorders. More recently, molecular approaches have been useful in further characterizing this group of diseases, albeit in a largely experimental context, with the detection of changes at the single gene level including mutations, amplification and epigenetic phenomena. Nevertheless, we remain largely ignorant of the genetic underpinnings of MDS. Here we briefly review the established role of cytogenetics in MDS, and emphasize recent advances in unraveling the genetics of MDS, with a view towards how such findings might facilitate our ability to understand, diagnose and treat these disorders in a more rational manner.

Entities:  

Mesh:

Year:  2006        PMID: 16522543     DOI: 10.1080/10245330500276691

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  1 in total

1.  Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy.

Authors:  Hagop M Kantarjian; Francis J Giles; Peter L Greenberg; Ron L Paquette; Eunice S Wang; Janice L Gabrilove; Guillermo Garcia-Manero; Kuolung Hu; Janet L Franklin; Dietmar P Berger
Journal:  Blood       Date:  2010-07-14       Impact factor: 22.113

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.